Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
Clinical trial NCT02339324 · COMPLETED
Trial details
- NCT number
- NCT02339324
- Sponsor
- Yana Najjar
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-06
- Primary completion
- 2019-09-01
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.